Skip to search formSkip to main contentSkip to account menu

FF 705

Known as: FF-705 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1992
1992
Alleviation of intestinal lesions by combined treatment with a 5-fluoro-2'-deoxyuridine (FUDR) derivative and alpha-difluoromethylornithine (DFMO)[correction of DMFO] in tumor-bearing mice.
alpha-Difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, reduced intestinal lesions in tumor-bearing mice… 
1988
1988
[In vivo distribution and activation of 5-FU--with special reference to biochemical modulation of intracellular metabolism].
5-FU is metabolized to FUTP and FdUMP in tumor cells and exhibits RNA- and DNA-directed cytotoxicity. Biochemical modulation of… 
1984
1984
[Phase II study of FF-705 by Clinical Cooperative Study Group].
Clinical efficacy of new fluorouridine derivative, FF-705, was studied in 108 patients with advanced malignant tumors. Partial… 
1984
1984
[Phase I study of a new floxuridine derivative, 2'-deoxy-3', 5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine (FF-705)].
A phase I study of a new floxuridine derivative, FF-705, was performed in patients with various types of solid tumors. Efficacy… 
1984
1984
[Chemical modification of anticancer agents from viewpoints of their pharmacokinetics].
Many derivatives modifying chemical structures have been synthesized from several drugs. These include following antibiotics… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)